11-09-2020, 04:13 PM
Always challenging to extrapolate between products, but Pfizer's apparent success suggests that the technology (mRNA vaccination) is viable, and that the target (the spike protein) can lead to immunity. Both of these bode well for Moderna's vaccine (an mRNA vaccine going after the spike protein), and to a lesser extent a lot of the other vaccines, which use the spike protein.
BC
BC